Burney Co. Takes Position in Globus Medical, Inc. $GMED

Burney Co. acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 12,345 shares of the medical device company’s stock, valued at approximately $1,064,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GMED. Annex Advisory Services LLC purchased a new stake in shares of Globus Medical in the 4th quarter valued at about $20,572,000. Kingdon Capital Management L.L.C. lifted its holdings in shares of Globus Medical by 51.6% during the third quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock worth $14,756,000 after purchasing an additional 87,650 shares during the period. Kennedy Capital Management LLC boosted its holdings in shares of Globus Medical by 44.6% in the third quarter. Kennedy Capital Management LLC now owns 490,949 shares of the medical device company’s stock valued at $28,117,000 after acquiring an additional 151,500 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Globus Medical by 71,618.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock valued at $62,555,000 after purchasing an additional 715,470 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Globus Medical by 510.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 266,532 shares of the medical device company’s stock worth $23,271,000 after purchasing an additional 222,841 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Stock Performance

Globus Medical stock opened at $76.23 on Thursday. The firm has a market capitalization of $10.35 billion, a price-to-earnings ratio of 17.73, a price-to-earnings-growth ratio of 1.63 and a beta of 0.95. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The stock’s fifty day moving average is $81.13 and its two-hundred day moving average is $86.97.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the previous year, the company posted $0.68 EPS. The business’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Insider Activity

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director owned 510,175 shares of the company’s stock, valued at $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 18.38% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently commented on GMED shares. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Stifel Nicolaus decreased their target price on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research report on Wednesday. Finally, Needham & Company LLC upped their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $105.42.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.